Relia Tech/Human GITR/TNFRSF18 Fc/20 µg/SFC-001S
市场价：
¥1500.00
美元价：
900.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Cat-Nr. | SFC-001S |
| Size | 20 µg |
| Price | 75 € |
| Source | CHO cells |
| Label | Fc-tag |
| Formulation | lyophilized |
| Purity Confirmation | ≥ 95% by SDS-PAGE gel and HPLC analyses. |
| Length [aa] | 369 |
| Molecular Weight | 40.6 kDa calculated |
| Endotoxin Levels | < 0.1 ng/µg of protein (<1EU/µg) |
| Biological Activity | Determined by its ability to bind recombinant human GITR Ligand/TNFSF18 in a functional ELISA. |
| Species Reactivity | Human |
| Synonyms | Tumor necrosis factor receptor superfamily member 18, Activation-inducible TNFR family receptor, Glucocorticoidinduced TNFR-related protein |
| Description | GITR, also known as tumor necrosis factor receptor superfamily 18 (TNFRSF18), is a member of the receptor family bearing the same name that is expressed on the surfaces of cells involved in both adaptive and innate immunity, including CD4+ T cells, CD8+ T cells, natural killer cells, B cells, macrophages, and dendritic cells. Like all other TNFRSF members, GITR regulates the duration, phenotype, and degree by which the immune system responds to antigens. The National Cancer Institute regards GITR as the 12th most important molecule involved in immunotherapy, as it plays a major role in modulating both inflammatory and immune responses. The receptor has attracted the attention of immunologists for its potential as a costimulatory immune checkpoint molecule in immunotherapy. Expressed in peripheral tissues as well as endothelial cells, GITR inhibits T cell receptor-induced apoptosis via its cross-linking mechanism, thereby creating an environment that promotes T cell longevity and survival. To accomplish this task, GITR initiates signal transduction by activating nuclear factor κB (NF-κB) along with the following specific mitogen-activated protein kinase (MAPK) pathways: extracellular signal-related kinases (ERKs), c-Jun N-terminal kinase (JNK), and p38. Several bone disorders, such as familial expansive osteolysis, autosomal recessive osteopetrosis and Paget’s disease, have been attributed to GITR mutations due to its key role in regulating osteoclast and lymph node development. The CHO cell-derived Recombinant Human GITR/TNFRSF18 Fc is a glycosylated, disulfide-linked homodimer of 738 amino-acid-residues whose monomer consists of a 136-amino-acid extracellular domain fused to the 231-amino-acid length Fc portion of human IgG by two glycine residues. The calculated molecular weight of monomeric CHO cell-derived Recombinant Human GITR/TNFRSF18 Fc is 40.6 kDa; however, due to glycosylation, it migrates at an apparent molecular weight of approximately 45-50 kDa by SDS-PAGE analysis under reducing conditions. |
| Protein Sequence | QRPTGGPGCG PGRLLLGTGT DARCCRVHTT RCCRDYPGEE CCSEWDCMCV QPEFHCGDPC CTTCRHHPCP PGQGVQSQGK FSFGFQCIDC ASGTFSGGHE GHCKPWTDCT QFGFLTVFPG NKTHNAVCVP GSPPAEGGPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK |
| Uniprot ID | Q9Y5U5 |
| Protein RefSeq | NP_004186.1 |
| mRNA RefSeq | NM_004195.2 |
品牌介绍
Receptor Ligand Technologies GmbH 公司（RELIA Tech ）位于德国不伦瑞克，是一家后基因组生物技术公司，该公司运用独特的技术专注于受体和配体的发现与研究，从而使商业化，产品广泛使用于科学研究，实验诊断和临床应用。瑞莱技术的灵活性和竞争力必将使其在这个快速整合的功能基因组学和蛋白组学的新时代发展壮大.RELIA公司提供的细胞因子，生长因子，重组蛋白产品一致内毒素检测项目，且内毒素水平非常低。 受体配体技术有限公司（RELIATech）是一家后基因组生物技术公司，致力于在配体与受体相互作用领域的新技术和新产品的发现和商业化，用于研究，诊断和临床领域。该公司位于德国不伦瑞克，由以下公司成立于2000年10月： 阿夫纳·亚永教授以色列魏兹曼科学研究所（WIS） 赫伯特·韦奇博士德国生物技术德国研究中心（GBF） Bernhard Barleon博士德国肿瘤生物学诊所（KTB） 创始人是从事细胞生长因子相互作用，酪氨酸激酶及其信号传导途径（涉及组织重塑，体内平衡和疾病）领域的细胞和分子生物学家，工作时间超过10年。特别是Herbert A. Weich博士和Bernhard Barleon博士从事血管生成，肿瘤血管生成和实体瘤进展领域的基础研究。 诸如“生长因子和细胞因子”之类的信号蛋白，连同其跨膜/“可溶性受体”和相关的激酶，在生理和病理生理条件下都作为关键的调节分子参与了所有高级生物的发育和功能。这些多肽调节细胞分化，组织重塑和体内平衡，并在各种疾病状态下被失调。由人类基因组计划编码新信号蛋白的新生长调节基因的发现，以及对它们功能的阐明，无疑将是未来十年的主要挑战之一。 RELIATech的使命是开发和商品化在“受体和配体相互作用”领域中有用的新产品，用于基础研究，药物开发和临床社区。RELIATech的灵活性和能力必将使其在功能基因组学和蛋白质组学的新时代迅速整合和扩展。
联络我们
